Engineering Challenges and Opportunities in Autologous Cellular Cancer Immunotherapy.

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Autologous cell therapies, including engineered T cells and dendritic cell vaccines, show promise for patient-specific cancer immunotherapy.
• Current approaches face significant hurdles in clinical efficacy, safety, and applicability across diverse patient populations.
• Tumor heterogeneity and antigen downregulation can lead to resistance in targeted immunotherapies, while broader approaches may suffer from weak T cell responses.

Approach:

• This review examines engineering strategies to address limitations in four classes of autologous cell therapies.
• Focus is placed on overcoming challenges such as genetic modification, T cell exhaustion, and immunotoxicity.
• Opportunities for enhancing immune responses against tumor-specific antigens are highlighted.

Key Points:

• Chimeric antigen receptor (CAR) T cells and tumor-infiltrating lymphocytes (TILs) face challenges in genetic modification, T cell exhaustion, and potential immunotoxicity.
• Dendritic cell (DC) vaccines targeting specific tumor antigens can elicit robust responses but are susceptible to tumor heterogeneity and antigen loss.
• Whole tumor cell vaccines and tumor lysate-loaded DC vaccines target a broader antigenic repertoire but may be limited by low-affinity T cell dominance.

Conclusions:

• Engineering advancements are crucial for improving the efficacy, safety, and accessibility of autologous cell therapies.
• Addressing challenges like tumor evolution and T cell dysfunction will expand the potential of these personalized cancer treatments.
• Further research into novel engineering approaches is needed to fully realize the therapeutic potential of autologous cell-based immunotherapies.